By adding in silent mutations near the edits they made to F508del, Liu’s team found that the mismatch repair system was less likely to undo edits. The new and improved prime editing system proved far ...

In December, the FDA approved Vertex’s vanzacaftor, tezacaftor and deutivacaftor (Alyftrek) for the treatment of cystic fibrosis in patients with at least one F508del mutation or another ...